Ken Griffin Pacira Bio Sciences, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 105,500 shares of PCRX stock, worth $2.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

105,500

Previous 41,000 157.32%

Holding current value

$2.09 Million

Previous $1.17 Million 35.38%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$11.7 - $28.46 $1.71 Million - $4.17 Million	146,471 Added 48.81%	446,533 $6.72 Million
Q2 2024 Aug 14, 2024	BUY	$25.5 - $31.51 $5.42 Million - $6.69 Million	212,384 Added 242.23%	300,062 $8.58 Million
Q1 2024 May 15, 2024	BUY	$27.7 - $35.48 $2.19 Million - $2.81 Million	79,145 Added 927.52%	87,678 $2.56 Million
Q4 2023 Feb 14, 2024	SELL	$26.32 - $34.31 $1.97 Million - $2.57 Million	-74,845 Reduced 89.77%	8,533 $287,000
Q3 2023 Nov 14, 2023	SELL	$30.68 - $40.09 $22.3 Million - $29.1 Million	-726,772 Reduced 89.71%	83,378 $2.56 Million
Q2 2023 Aug 14, 2023	BUY	$36.12 - $47.5 $13.8 Million - $18.1 Million	381,750 Added 89.11%	810,150 $32.5 Million
Q1 2023 May 15, 2023	BUY	$35.53 - $43.38 $5.01 Million - $6.12 Million	141,034 Added 49.08%	428,400 $17.5 Million
Q4 2022 Feb 14, 2023	BUY	$38.19 - $57.45 $10.2 Million - $15.3 Million	265,825 Added 1234.04%	287,366 $11.1 Million
Q3 2022 Nov 14, 2022	BUY	$51.24 - $58.89 $1.1 Million - $1.27 Million	21,541 New	21,541 $1.15 Million
Q1 2022 May 16, 2022	BUY	$60.03 - $76.49 $185,732 - $236,660	3,094 Added 2.95%	107,884 $8.23 Million
Q4 2021 Feb 14, 2022	BUY	$47.97 - $62.21 $4.41 Million - $5.72 Million	91,990 Added 718.67%	104,790 $6.31 Million
Q3 2021 Nov 15, 2021	SELL	$54.64 - $61.3 $3.58 Million - $4.02 Million	-65,514 Reduced 83.66%	12,800 $717,000
Q2 2021 Aug 16, 2021	BUY	$59.18 - $69.99 $1.95 Million - $2.31 Million	32,964 Added 72.69%	78,314 $4.75 Million
Q1 2021 May 17, 2021	SELL	$59.31 - $78.82 $3.74 Million - $4.97 Million	-63,114 Reduced 58.19%	45,350 $3.18 Million
Q4 2020 Feb 16, 2021	SELL	$50.47 - $66.26 $464,223 - $609,459	-9,198 Reduced 7.82%	108,464 $6.49 Million
Q3 2020 Nov 16, 2020	SELL	$51.97 - $63.0 $2.62 Million - $3.18 Million	-50,441 Reduced 30.01%	117,662 $7.07 Million
Q2 2020 Aug 14, 2020	BUY	$30.8 - $52.47 $2.58 Million - $4.4 Million	83,770 Added 99.33%	168,103 $8.82 Million
Q1 2020 May 15, 2020	SELL	$28.4 - $50.7 $6.22 Million - $11.1 Million	-219,113 Reduced 72.21%	84,333 $2.83 Million
Q4 2019 Feb 14, 2020	BUY	$36.31 - $46.83 $160,635 - $207,175	4,424 Added 1.48%	303,446 $13.7 Million
Q3 2019 Nov 14, 2019	SELL	$35.66 - $44.99 $2.7 Million - $3.4 Million	-75,602 Reduced 20.18%	299,022 $11.4 Million
Q2 2019 Aug 14, 2019	BUY	$36.57 - $47.97 $7.02 Million - $9.21 Million	192,044 Added 105.18%	374,624 $16.3 Million
Q1 2019 May 15, 2019	BUY	$36.47 - $42.17 $486,546 - $562,589	13,341 Added 7.88%	182,580 $0
Q4 2018 Feb 14, 2019	SELL	$41.31 - $52.16 $1.87 Million - $2.36 Million	-45,193 Reduced 21.08%	169,239 $7.28 Million
Q3 2018 Nov 13, 2018	BUY	$32.85 - $52.0 $5.91 Million - $9.35 Million	179,795 Added 519.08%	214,432 $0
Q2 2018 Aug 10, 2018	BUY	$27.5 - $39.8 $294,910 - $426,815	10,724 Added 44.85%	34,637 $0
Q1 2018 May 11, 2018	SELL	$29.98 - $46.35 $6.44 Million - $9.95 Million	-214,654 Reduced 89.98%	23,913 $745,000
Q4 2017 Feb 09, 2018	BUY	$31.85 - $46.95 $5.65 Million - $8.33 Million	177,445 Added 290.31%	238,567 $10.9 Million
Q3 2017 Nov 09, 2017	BUY	$35.7 - $39.5 $2.18 Million - $2.41 Million	61,122	61,122 $2.3 Million

Others Institutions Holding PCRX

# of Institutions

263

Shares Held

50.4M

Call Options Held

429K

Put Options Held

391K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $908M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account